<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31629403</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>Comparative assessment and monitoring of deterioration of articulatory organs using subjective and objective tools among patients with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>241</StartPage><MedlinePgn>241</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">241</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-019-1484-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a fatal degenerative disease of a rapid course. In 25% of ALS sufferers, speech disorders occur as prodromal symptoms of the disease. Impaired communication affects physical health and has a negative impact on mental and emotional condition. In this study, we assessed which domains of speech are particularly affected in ALS. Subsequently, we estimated possible correlations between the ALS patients' subjective perception of their speech quality and an objective assessment of the speech organs carried out by an expert.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study group consisted of 63 patients with sporadic ALS. The patients were examined for articulatory functions by means of Voice Handicap Index (VHI) and the Frenchay Dysarthria Assessment (FDA).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">On the basis of the VHI scores, the entire cohort was divided into 2 groups: group I (40 subjects) with mild speech impairment, and group II (23 subjects) displaying moderate and profound speech deficits. In an early phase of ALS, changes were typically reported in the tongue, lips and soft palate. The FDA and VHI-based measurements revealed a high, positive correlation between the objective and subjective evaluation of articulation quality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Deterioration of the articulatory organs resulted in the reduction of social, physical and emotional functioning. The highly positive correlation between the VHI and FDA scales seems to indicate that the VHI questionnaire may be a reliable, self-contained tool for monitoring the course and progression of speech disorders in ALS.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">NCT02193893 .</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pawlukowska</LastName><ForeName>Wioletta</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-4974-4292</Identifier><AffiliationInfo><Affiliation>Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University, &#x17b;o&#x142;nierska 54, Szczecin, 71-210, Poland. wsna@o2.pl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Pomeranian Medical University, Unii Lubelskiej 1, Szczecin, 71-210, Poland. wsna@o2.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumert</LastName><ForeName>Bart&#x142;omiej</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of General Pathology, Pomeranian Medical University, Unii Lubelskie 1, Szczecin, 71-252, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Go&#x142;&#x105;b-Janowska</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Pomeranian Medical University, Unii Lubelskiej 1, Szczecin, 71-210, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meller</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Pomeranian Medical University, Unii Lubelskiej 1, Szczecin, 71-210, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machowska-Sempruch</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Pomeranian Medical University, Unii Lubelskiej 1, Szczecin, 71-210, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>We&#x142;nicka</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Pomeranian Medical University, Unii Lubelskiej 1, Szczecin, 71-210, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paczkowska</LastName><ForeName>Edyta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of General Pathology, Pomeranian Medical University, Unii Lubelskie 1, Szczecin, 71-252, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotter</LastName><ForeName>Iwona</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University, &#x17b;o&#x142;nierska 54, Szczecin, 71-210, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machali&#x144;ski</LastName><ForeName>Bogus&#x142;aw</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of General Pathology, Pomeranian Medical University, Unii Lubelskie 1, Szczecin, 71-252, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowacki</LastName><ForeName>Przemys&#x142;aw</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Pomeranian Medical University, Unii Lubelskiej 1, Szczecin, 71-210, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02193893</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013060" MajorTopicYN="N">Speech</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013064" MajorTopicYN="N">Speech Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013066" MajorTopicYN="N">Speech-Language Pathology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Dysarthria</Keyword><Keyword MajorTopicYN="N">Frenchay Dysarthria Assessment</Keyword><Keyword MajorTopicYN="N">Speech disorders</Keyword><Keyword MajorTopicYN="N">Voice Handicap Index</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31629403</ArticleId><ArticleId IdType="pmc">PMC6800986</ArticleId><ArticleId IdType="doi">10.1186/s12883-019-1484-2</ArticleId><ArticleId IdType="pii">10.1186/s12883-019-1484-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goodall EF, Morrison KE. Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert Rev Mol Med. 2006;8:1&#x2013;22. doi: 10.1017/S1462399406010854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1462399406010854</ArticleId><ArticleId IdType="pubmed">16723044</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavares de Andrade HM, Cintra VP, de Albuquerque M, Piccinin CC, Bonadia LC, Duarte Couteiro RE, et al. Intermediate-length CAG repeat in ATXN2 is associated with increased risk for amyotrophic lateral sclerosis in Brazilian patients. Neurobiol Aging. 2018;69:292.e15&#x2013;292.e18. doi: 10.1016/j.neurobiolaging.2018.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.04.020</ArticleId><ArticleId IdType="pubmed">29934271</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;13(377):162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;4(390):2084&#x2013;2098.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy J. Unilateral upper motor neuron dysarthria. In: Motor speech disorders: substrates, differential diagnosis, and management, 3rd: Mosby; Elsevier Health Sciences; 2012. p. 255&#x2013;73.</Citation></Reference><Reference><Citation>Tomik B, Guiloff RJ. Dysarthria in amyotrophic lateral sclerosis: a review. Amyotroph Lateral Scler. 2010;11:4&#x2013;15. doi: 10.3109/17482960802379004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802379004</ArticleId><ArticleId IdType="pubmed">20184513</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S, Sieniawski M, Kollewe K, Rath KJ, Krampfl K, Zapf A, et al. Speech therapy and communication device: impact on quality of life and mood in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:20&#x2013;25. doi: 10.3109/17482968.2012.692382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.692382</ArticleId><ArticleId IdType="pubmed">22871079</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts CR, Vanryckeghem M. Laryngeal dysfunction in amyotrophic lateral sclerosis: a review and case report. BMC Ear Nose Throat Disord. 2001;1:1. doi: 10.1186/1472-6815-1-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6815-1-1</ArticleId><ArticleId IdType="pmc">PMC60006</ArticleId><ArticleId IdType="pubmed">11722802</ArticleId></ArticleIdList></Reference><Reference><Citation>Mefferd AS, Green JR, Pattee G. A novel fixed-target task to determine articulatory speed constraints in persons with amyotrophic lateral sclerosis. J Commun Disord. 2012;45:35&#x2013;45. doi: 10.1016/j.jcomdis.2011.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcomdis.2011.09.002</ArticleId><ArticleId IdType="pmc">PMC3251716</ArticleId><ArticleId IdType="pubmed">22000045</ArticleId></ArticleIdList></Reference><Reference><Citation>Mefferd AS, Pattee GL, Green JR. Speaking rate effects on articulatory pattern consistency in talkers with mild ALS. Clin Linguist Phon. 2014;28:799&#x2013;811. doi: 10.3109/02699206.2014.908239.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/02699206.2014.908239</ArticleId><ArticleId IdType="pmc">PMC4675322</ArticleId><ArticleId IdType="pubmed">24724615</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunusova Y, Weismer GG, Lindstrom MJ. Classifications of vocalic segments from articulatory kinematics: healthy controls and speakers with dysarthria. J Speech Lang Hear Res. 2011;54:1302&#x2013;1311. doi: 10.1044/1092-4388(2011/09-0193).</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/1092-4388(2011/09-0193)</ArticleId><ArticleId IdType="pubmed">21646421</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong P, Yunusova Y, Wang J, Green JR. Predicting early bulbar decline in amyotrophic lateral sclerosis: a speech subsystem approach. Behav Neurol. 2015;2015:183027. doi: 10.1155/2015/183027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/183027</ArticleId><ArticleId IdType="pmc">PMC4468279</ArticleId><ArticleId IdType="pubmed">26136624</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong P, Yunusova Y, Wang J, Zinman L, Pattee LG, Berry JD, et al. Predicting speech intelligibility decline in amyotrophic lateral sclerosis based on the deterioration of individual speech subsystems. PLoS One. 2016;11:e0154971. doi: 10.1371/journal.pone.0154971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0154971</ArticleId><ArticleId IdType="pmc">PMC4858181</ArticleId><ArticleId IdType="pubmed">27148967</ArticleId></ArticleIdList></Reference><Reference><Citation>Couratier P, Torny F, Lacoste M. Functional rating scales for amyotrophic lateral sclerosis. Rev Neurol (Paris) 2006;162:502&#x2013;507. doi: 10.1016/S0035-3787(06)75041-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0035-3787(06)75041-X</ArticleId><ArticleId IdType="pubmed">16585911</ArticleId></ArticleIdList></Reference><Reference><Citation>Enderby P, Palmer R. FDA-2. The Frenchay Dysarthria Assessment. Examiner&#x2019;s Manual. 2. Austin: Pro-Ed; 2008.</Citation></Reference><Reference><Citation>Yorkston K, Beukelman DR, Hakel M, Dorsey M. Sentence intelligibility test for windows. Lincoln: Institute for Rehabilitation Science and Engineering at Madonna Rehabilitation Hospital; 2007.</Citation></Reference><Reference><Citation>Ball L, Beukelman D, Ullman C, Maassen K, Pattee G. Monitoring speaking rate by telephone for persons with amyotrophic lateral sclerosis. J Med Speech Lan Path. 2005;13:233&#x2013;240.</Citation></Reference><Reference><Citation>Kent RD, Vorperian HK, Kent JF, Duffy JR. Voice dysfunction in dysarthria: application of the multi-dimensional voice program. J Commun Disord. 2003;36:281&#x2013;306. doi: 10.1016/S0021-9924(03)00016-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9924(03)00016-9</ArticleId><ArticleId IdType="pubmed">12837587</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson BH, Jonson A, Grywalski C, et al. The voice handicap index (VHI): development and validation. Am J Speech Lang Pathol. 1997;6:66&#x2013;70. doi: 10.1044/1058-0360.0603.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/1058-0360.0603.66</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobu&#x15b; A, Baumert B, Litwi&#x144;ska Z, Go&#x142;&#x105;b-Janowska M, St&#x119;pniewski J, Kotowski M, et al. Safety and Feasibility of Lin- Cells Administration to ALS Patients: A Novel View on Humoral Factors and miRNA Profiles. Int J Mol Sci. 2018;27(19):E1312. doi: 10.3390/ijms19051312.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19051312</ArticleId><ArticleId IdType="pmc">PMC5983708</ArticleId><ArticleId IdType="pubmed">29702606</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lortie CL, Thibeault M, Guitton MJ, Tremblay P. Effects of age on the amplitude, frequency and perceived quality of voice. Age (Dordr) 2015;37:117. doi: 10.1007/s11357-015-9854-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-015-9854-1</ArticleId><ArticleId IdType="pmc">PMC5005868</ArticleId><ArticleId IdType="pubmed">26578457</ArticleId></ArticleIdList></Reference><Reference><Citation>Franic DM, Bramle RE, Bothe AC. Psychometric evaluation of disease specific quality of life instruments in voice disorders. J Voice. 2005;19:300&#x2013;301. doi: 10.1016/j.jvoice.2004.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvoice.2004.03.003</ArticleId><ArticleId IdType="pubmed">15907445</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson-Clement C, Letanneux A, Baille G, Cuartero MC, V&#xe9;ron-Delor L, Robieux C, et al. Psychosocial impact of dysarthria: the patient-reported outcome as part of the clinical management. Neurodegener Dis. 2019;21:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">31112944</ArticleId></ArticleIdList></Reference><Reference><Citation>Biddle AK, Watson LR, Hooper CR, Lohr KN, Sutton SF. Criteria for determining disability in speech-language disorders. Evid Rep Technol Assess (Summ). 2002;(52):1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4781600</ArticleId><ArticleId IdType="pubmed">15523744</ArticleId></ArticleIdList></Reference><Reference><Citation>Behlau M, dos Santos LDMA, Oliveira G. Cross-cultural adaptation and validation of the voice handicap index into Brazilian Portuguese. J Voice. 2011;25:354&#x2013;359. doi: 10.1016/j.jvoice.2009.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvoice.2009.09.007</ArticleId><ArticleId IdType="pubmed">20434874</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonetti A, Bonetti L. Cross-cultural adaptation and validation of the voice handicap index into Croatian. J Voice. 2013;27:130&#x2013;137. doi: 10.1016/j.jvoice.2012.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvoice.2012.07.006</ArticleId><ArticleId IdType="pubmed">23044461</ArticleId></ArticleIdList></Reference><Reference><Citation>Helidoni ME, Murry T, Moschandreas J, Lionis C, Printza A, Velegrakis GA. Cross-cultural adaptation and validation of the voice handicap index into Greek. J Voice. 2010;24:221&#x2013;227. doi: 10.1016/j.jvoice.2008.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvoice.2008.06.005</ArticleId><ArticleId IdType="pubmed">18752925</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler A, Ottaviani F, Mozzanica F, Bachmann C, Favero E, Schettino I, et al. Cross-cultural adaptation and validation of the voice handicap index into Italian. J Voice. 2010;24:708&#x2013;714. doi: 10.1016/j.jvoice.2009.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvoice.2009.05.006</ArticleId><ArticleId IdType="pubmed">20083383</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinite B, Sokolovs J. Adaptation and validation of the voice handicap index in Latvian. J Voice. 2014;28:452&#x2013;457. doi: 10.1016/j.jvoice.2014.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvoice.2014.01.008</ArticleId><ArticleId IdType="pubmed">24690553</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruszewicz A, Obr&#x119;bowski A, Wiskirska-Wo&#x17a;nica B, Wojnowski W. W sprawie kompleksowej oceny g&#x142;osu &#x2013; w&#x142;asna modyfikacja testu samooceny niesprawno&#x15b;ci g&#x142;osu (Voice Handicap Idex) Otolaryngol Pol. 2004;58:547&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311601</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlukowska W, Szyli&#x144;ska A, Kotl&#x119;ga D, Rotter I, Nowacki P. Differences between subjective and objective assessment of speech deficiency in Parkinson disease. J Voice. 2018;32(6):715&#x2013;722. doi: 10.1016/j.jvoice.2017.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvoice.2017.08.018</ArticleId><ArticleId IdType="pubmed">29122413</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth C, Glaze L, Goding G, David W. Spasmodic dysphonia symptoms as initial presentation of amyotrophic lateral sclerosis. J Voice. 1996;10:362&#x2013;367. doi: 10.1016/S0892-1997(96)80028-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0892-1997(96)80028-2</ArticleId><ArticleId IdType="pubmed">8943140</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfield DB, Viswanath N, Herbrich KE, Nudelman HB. Evaluation of the speech motor control system in amyotrophic lateral sclerosis. J Voice. 1991;5:224&#x2013;230. doi: 10.1016/S0892-1997(05)80190-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0892-1997(05)80190-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Yorkston KM, Strand E, Miller R, Hillel A, Smith K. Speech deterioration in amyotrophic lateral sclerosis: implications for the timing of intervention. Int J Lang Commun Disord. 2018;53:385&#x2013;392. doi: 10.1111/1460-6984.12357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1460-6984.12357</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunusova Y, Weismer G, Westbury JR, Lindstrom M. Articulatory movements during vowels in speakers with dysarthria and normal controls. J Speech Lang Hear Res. 2008;51:596&#x2013;611. doi: 10.1044/1092-4388(2008/043).</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/1092-4388(2008/043)</ArticleId><ArticleId IdType="pubmed">18506038</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson E, Yorkston K, Britton D. Dysarthria in amyotrophic lateral sclerosis: a systematic review of characteristics, speech treatment, and AAC options. J Med Speech-Lang Pathol. 2011;19:12&#x2013;30.</Citation></Reference><Reference><Citation>Barkmeier J, Jordan LS, Robin DA, Schum RL. Inexperienced Listener Ratings of Dysarthric Speaker intelligibility and Physical Appearance. In: Moore CA, editor. Dysarthria and apraxia of speech: Perspectives on management. Baltimore: Paul H. Brookes Publishing Co; 1991. pp. 65&#x2013;75.</Citation></Reference><Reference><Citation>Green JR, Yunusova Y, Kuruvilla MS, Wang J, Pattee GL, Synhorst L, et al. Bulbar speech motor assessment in ALS: challenges and future directions. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:494&#x2013;500. doi: 10.3109/21678421.2013.817585.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.817585</ArticleId><ArticleId IdType="pmc">PMC3833808</ArticleId><ArticleId IdType="pubmed">23898888</ArticleId></ArticleIdList></Reference><Reference><Citation>DePaul R, Brooks BR. Multiple orofacial indices in amyotrophic lateral sclerosis. J Speech Hear Res. 1993;36:1158&#x2013;1167. doi: 10.1044/jshr.3606.1158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/jshr.3606.1158</ArticleId><ArticleId IdType="pubmed">8114482</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald ER, Wiedenfeld SA, Hillel A, Carpenter CL, Walter RA. Survival in amyotrophic lateral sclerosis: the role of psychological factors. Arch Neurol. 1994;51:17&#x2013;23. doi: 10.1001/archneur.1994.00540130027010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1994.00540130027010</ArticleId><ArticleId IdType="pubmed">8274106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Salas T, Fajardo ML, Iv&#xe1;&#xf1;ez L, Rodr&#xed;guez- Santos F. Self-perceived emotional functioning of Spanish patients with amyotrophic lateral sclerosis: a longitudinal study. Front Psychol. 2013;3:609. doi: 10.3389/fpsyg.2012.00609.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2012.00609</ArticleId><ArticleId IdType="pmc">PMC3539828</ArticleId><ArticleId IdType="pubmed">23316181</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagnini F. Psychological well-being and quality of life in amyotrophic lateral sclerosis: a review. Int J Psychol. 2013;48:194&#x2013;205. doi: 10.1080/00207594.2012.691977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00207594.2012.691977</ArticleId><ArticleId IdType="pubmed">22731673</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulla S, Vielhaber S, Kollewe K, Machts J, Heinze HJ, Dengler R, et al. The impact of physical impairment on emotional well-being in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:392&#x2013;397. doi: 10.3109/21678421.2014.932380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.932380</ArticleId><ArticleId IdType="pubmed">25008979</ArticleId></ArticleIdList></Reference><Reference><Citation>Millul A, Beghi E, Logroscino G, Micheli A, Vitelli E, Zardi A. Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology. 2005;25:114&#x2013;119. doi: 10.1159/000086353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000086353</ArticleId><ArticleId IdType="pubmed">15956808</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunusova Y, Green JR, Wang J, Pattee G, Zinman L. A protocol for comprehensive assessment of bulbar dysfunction in amyotrophic lateral sclerosis. J Vis Exp. 2011;21:2422. doi: 10.3791/2422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/2422</ArticleId><ArticleId IdType="pmc">PMC3197394</ArticleId><ArticleId IdType="pubmed">21372794</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology. 2010;75:1270&#x2013;1276. doi: 10.1212/WNL.0b013e3181f61311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181f61311</ArticleId><ArticleId IdType="pubmed">20921512</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogden A, Foley G, Henderson RD, James N, Aoun SM. Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach. J Multidiscip Healthc. 2017;10:205&#x2013;215. doi: 10.2147/JMDH.S134992.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JMDH.S134992</ArticleId><ArticleId IdType="pmc">PMC5446964</ArticleId><ArticleId IdType="pubmed">28579792</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>